PS Ratio Chart

View PS Ratio for RHHBY.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View PS Ratio Chart
Start Trial

Historical PS Ratio Data

View and export this data back to 2005. Start Trial.
Date Value
August 24, 2026 4.818
August 21, 2026 4.871
August 20, 2026 4.800
August 19, 2026 4.879
August 18, 2026 4.655
August 17, 2026 4.578
August 14, 2026 4.571
August 13, 2026 4.652
August 12, 2026 4.738
August 11, 2026 4.747
August 10, 2026 4.815
August 07, 2026 4.801
August 06, 2026 4.709
August 05, 2026 4.729
August 04, 2026 4.646
August 03, 2026 4.618
July 31, 2026 4.583
July 30, 2026 4.634
July 29, 2026 4.609
July 28, 2026 4.738
July 27, 2026 4.592
July 24, 2026 4.586
July 23, 2026 4.521
July 22, 2026 4.334
July 21, 2026 4.288
Date Value
July 20, 2026 4.276
July 17, 2026 4.326
July 16, 2026 4.314
July 15, 2026 4.291
July 14, 2026 4.205
July 13, 2026 4.234
July 10, 2026 4.351
July 09, 2026 4.361
July 08, 2026 4.340
July 07, 2026 4.374
July 06, 2026 4.325
July 02, 2026 4.447
July 01, 2026 4.219
June 30, 2026 4.305
June 29, 2026 4.557
June 26, 2026 4.484
June 25, 2026 4.495
June 24, 2026 4.440
June 23, 2026 4.364
June 22, 2026 4.257
June 18, 2026 4.311
June 17, 2026 4.426
June 16, 2026 4.432
June 15, 2026 4.421
June 12, 2026 4.477

Price to Sales Ratio Definition

The Price to Sales Ratio (PS Ratio) is calculated by taking the stock price / revenue per share (ttm). This metric is considered a valuation metric that confirms whether the sales of a company justifies the stock price. There isn't necesarily an optimum PS ratio, since different industries will have different ranges of PS Ratios. Because of this, PS Ratio is great to evaluate from a relative standpoint with other similar companies. PS Ratio might also be a handy metric for companies that are not profitable yet, since they might be valued moreso by their overall sales and potential of becoming profitable in the future.

Read full definition.

PS Ratio Range, Past 5 Years

View PS Ratio Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

PS Ratio Benchmarks

View PS Ratio Benchmarks
Start Trial
Novartis AG 5.551
Eli Lilly & Co. 14.22
AstraZeneca PLC 8.606
Merck & Co., Inc. 5.641
Pfizer Inc. 2.506

PS Ratio Related Metrics